Dual Immune Checkpoint Targeting Nanobody Therapy for Malignant Melanoma: ENTPD1 and PDCD1 Inhibition

VHH-P473 is a novel humanized nanobody-based biotherapeutic candidate engineered to target both ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) and programmed cell death 1 (PDCD1). Currently in the Biological Testing phase, VHH-P473 leverages a bispecific modality to modulate two critical immune checkpoints implicated in tumor immune evasion. This dual-action approach holds significant therapeutic potential for the treatment of malignant melanoma, a cancer characterized by aggressive progression and resistance to conventional treatments. By selectively engaging with ENTPD1 and PDCD1, VHH-P473 aims to enhance antitumor immune responses and address important unmet clinical needs in melanoma therapy.

Licensing Opportunity

VHH-P473 is actively offered for out-licensing collaborations. Partners interested in co-development, licensing, or commercial alliances are invited to discuss opportunities to accelerate clinical translation and maximize the value of this innovative immunotherapy asset.

Development Phase

Modality

VHH-P473 is a homodimeric bispecific antibody fusion construct composed of two distinct polypeptide chains. One chain features an anti-PD-1 antibody variable light chain fused to its constant region, while the other consists of an anti-PD-1 variable heavy chain fused to its constant region, along with two anti-CD39-humanized nanobodies. The use of nanobody elements—single-domain antibody fragments with a small molecular footprint—confers significant advantages such as enhanced tissue penetration, high stability, and improved manufacturability. This innovative structural design enables VHH-P473 to access and modulate targets within the tumor microenvironment more effectively, contributing to its therapeutic promise for malignant melanoma.

Target

ENTPD1 and PDCD1 are critical molecular targets in cancer immunotherapy. ENTPD1 is an ectoenzyme expressed predominantly on immune cells and within the tumor microenvironment, where it regulates extracellular nucleotide metabolism and contributes to immunosuppression. PDCD1, an inhibitory receptor on T cells, plays a pivotal role in downregulating immune responses and promoting tumor escape. Both ENTPD1 and PDCD1 are highly expressed in malignant melanoma and associated with poor prognosis. Therapeutic inhibition of ENTPD1 can reduce adenosine-mediated immunosuppression, while blockade of PDCD1 facilitates T cell activation. VHH-P473’s strategy of dual ENTPD1 and PDCD1 targeting provides a rational and strategic approach to overcoming multiple resistance mechanisms in melanoma, offering significant potential for improved patient outcomes.

Mechanism of Action

VHH-P473 operates as an immune checkpoint inhibitor by simultaneously antagonizing ENTPD1 and PDCD1. By binding to ENTPD1, the nanobody component interferes with the enzyme's ability to generate immunosuppressive adenosine, thereby enhancing antitumor immune activity. Concurrently, blockade of PDCD1 lifts inhibitory signaling on T cells, resulting in increased activation and sustained anti-cancer responses. Through its bispecific architecture, VHH-P473 brings together the functional properties of nanobodies and full-length antibody fragments, supporting versatility for additional molecular engineering such as ADC conjugation or further bispecific expansions. This mechanism is designed to produce a more robust and sustained immunological attack on melanoma tumors.

Malignant Melanoma

Malignant melanoma is a highly aggressive skin cancer arising from melanocytes, noted for its high metastatic potential and significant mortality risk. The incidence of malignant melanoma has been rising globally, with significant variation across different geographic regions and populations. Despite advances in targeted therapies and immune checkpoint inhibitors, many patients experience relapse, disease progression, or therapeutic resistance. Current standard-of-care approaches include surgical resection, chemotherapy, radiotherapy, targeted agents, and immune-based therapies, yet significant challenges remain—especially in advanced or refractory cases. Limitations include the development of resistance, immune escape, and systemic toxicity. There is a clear unmet medical need for innovative modalities that address tumor immune evasion and enhance patient survival. VHH-P473, by targeting both ENTPD1 and PDCD1, represents a promising next-generation approach to overcome these challenges, potentially providing improved efficacy and broadening therapeutic options for patients with malignant melanoma.